Evidence map›Paper›PMID 31360432›Full record

ReviewJournal of thyroid research2019

Medullary Thyroid Carcinoma: An Update on Imaging.

Sergiy V Kushchayev, Yevgeniya S Kushchayeva, Sri Harsha Tella, Tetiana Glushko, Karel Pacak, Oleg M Teytelboym

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of thyroid research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. A prospective, exploratory study ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. The utility ofThyroid research · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Long-Term Follow-Up in Medullary Thyroid Carcinoma Patients.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  14. What Is New in Diagnostics and Management of Medullary Thyroid Carcinoma.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025
    Review
  15. [Frontiers in endocrinology · 2025
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sergiy V Kushchayev *Moffitt Cancer Center, Department of Radiology, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.ORCID https://orcid.org/0000-0002-1373-5255
Yevgeniya S Kushchayeva *Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda 10, Center Dr, Bethesda, MD 20892, USA.
Sri Harsha TellaDepartment of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of South Carolina School of Medicine, 6311 Garners Ferry Rd, Columbia, SC, USA.ORCID https://orcid.org/0000-0001-8878-1283
Tetiana GlushkoDepartment of Radiology, Mercy Catholic Medical Center, 1500 Lansdowne Ave, Darby, PA 19023, USA.
Karel PacakEunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD/NIH), 10 Center Dr, Bethesda, MD 20892, USA.
Oleg M TeytelboymDepartment of Radiology, Mercy Catholic Medical Center, 1500 Lansdowne Ave, Darby, PA 19023, USA.

Funding

Diagnosis &Pathophysiology of PheochromocytomaZ01HD008735 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PACAK, KAREL · 2001 to 2008
$1.7M
Intramural NIH HHS Z01 HD008735
6 · The paper itself

Abstract

Medullary thyroid carcinoma (MTC), arising from the parafollicular C cells of the thyroid, accounts for 1-2% of thyroid cancers. MTC is frequently aggressive and metastasizes to cervical and mediastinal lymph nodes, lungs, liver, and bones. Although a number of new imaging modalities for directing the management of oncologic patients evolved over the last two decades, the clinical application of these novel techniques is limited in MTC. In this article, we review the biology and molecular aspects of MTC as an important background for the use of current imaging modalities and approaches for this tumor. We discuss the modern and currently available imaging techniques-advanced magnetic resonance imaging (MRI)-based techniques such as whole-body MRI, dynamic contrast-enhanced (DCE) technique, diffusion-weighted imaging (DWI), positron emission tomography/computed tomography (PET/CT) with 18F-FDOPA and 18F-FDG, and integrated positron emission tomography/magnetic resonance (PET/MR) hybrid imaging-for primary as well as metastatic MTC tumor, including its metastatic spread to lymph nodes and the most common sites of distant metastases: lungs, liver, and bones.

Identifiers

PMID31360432
PMCPMC6642782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.